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The fundamental importance of the hypothalamus in
the regulation of autonomic and cardiovascular func-
tions is well established. However, the molecular
processes involved are not well understood. Here,
we show that the mammalian (or mechanistic) target
of rapamycin (mTOR) signaling in the hypothalamus
is tied to the activity of the sympathetic nervous sys-
tem and to cardiovascular function. Modulation of
mTOR complex 1 (mTORC1) signaling caused dra-
matic changes in sympathetic traffic, blood flow,
and arterial pressure. Our data also demonstrate
the importance of hypothalamic mTORC1 signaling
in transducing the sympathetic and cardiovascular
actions of leptin. Moreover, we show that the PI3K
pathway links the leptin receptor to mTORC1
signaling and that changes in its activity impact sym-
pathetic traffic and arterial pressure. These findings
establish mTORC1 activity in the hypothalamus as
a key determinant of sympathetic and cardiovascular
regulation and suggest that dysregulated hypotha-
lamic mTORC1 activity may influence the develop-
ment of cardiovascular diseases.
INTRODUCTION
The evolutionarily conserved mammalian (or mechanistic) target
of rapamycin (mTOR) protein belongs to the phosphatidylinosi-
tol-kinase-related kinase family (Laplante and Sabatini, 2012).
mTOR is critically involved in the regulation of a number of
cellular functions, including protein synthesis, cell growth and
proliferation, ribosome and mitochondria biogenesis, cytoskel-
eton organization, and autophagy (Hay and Sonenberg, 2004;
Mamane et al., 2006; Wullschleger et al., 2006). mTOR activity
is modulated by various cues arising from growth factors, stress,
nutrients, and energy status.
Active mTOR interacts with several other proteins, leading to
the formation of two functionally distinct large complexes
(mTORC1 and mTORC2) that can be distinguished from each
other based on their unique compositions and the downstreamCpathways associated with each complex (Wullschleger et al.,
2006; Laplante and Sabatini, 2012). For instance, activated
mTORC1 causes the phosphorylation of S6 kinase (S6K) and
its downstream effector, the ribosomal protein S6 (Laplante
and Sabatini, 2012).
In the central nervous system, the mTOR pathway contributes
to the regulation of a wide range of processes including synaptic
plasticity, neuronal excitability, learning, and memory (Jaworski
and Sheng, 2006; Swiech et al., 2008). Dysregulated mTOR
signaling has been implicated in a number of neurological
disorders such as tuberous sclerosis and epilepsy, as well as
neurodegenerative diseases including Alzheimer’s disease and
Parkinson’s disease (Bove´ et al., 2011; Swiech et al., 2008).
The proven beneficial effects of rapamycin and its analogs in
cellular and animal models of various neurodegenerative dis-
eases have led to significant efforts to pharmacologically target
the mTOR pathway in neurodegeneration (Bove´ et al., 2011).
Recently, increasing attention has been paid to mTOR sig-
naling in the hypothalamus, a region that has a well-known
role in homeostasis through coordination of the regulation of
several physiological processes. For instance, although mTOR
and S6K are widely expressed in the brain, modulation of their
activity by changes in body energy status was found to be limited
to specific neurons of the hypothalamus in rats (Cota et al.,
2006). Altering mTORC1 signaling in the hypothalamus affected
food intake and body weight (Cota et al., 2006; Blouet et al.,
2008), peripheral insulin sensitivity (Ono et al., 2008), and repro-
ductive function (Roa et al., 2009). Moreover, hypothalamic
mTORC1 was found to be critically involved in mediating the
anorectic and weight-reducing effects of leptin (Cota et al.,
2006). The well-established role of the hypothalamus in
autonomic and cardiovascular regulation (Dampney et al.,
2005; Guyenet, 2006; Nakamura et al., 2009) led us to hypothe-
size that hypothalamic mTORC1 signaling is involved in the
control of the sympathetic nervous system and cardiovascular
function.
RESULTS AND DISCUSSION
Leucine Increases HypothalamicmTORC1, Sympathetic
Outflow, and Arterial Pressure
To test our hypothesis, we took advantage of the unique ability of
leucine, a branched amino acid, to activate mTORC1 signalingell Metabolism 17, 599–606, April 2, 2013 ª2013 Elsevier Inc. 599
Figure 1. Sympathetic and Hemodynamic Responses Evoked by Hypothalamic Action of Leucine
(A) Representative western blots of p-S6K (Thr389) and total S6K in hypothalamic GT1-7 cells that were treated with 10 mM of leucine or valine (n = 5 each).
(B and C) Effects of i.c.v. injection of leucine (5 mg) on p-S6K (Thr389, B) and p-S6 (Ser240/244, C) in the mediobasal hypothalamus of Sprague-Dawley rats (n = 3
each). AU, arbitrary units.
(D–F) Renal SNA response to i.c.v. leucine and valine in rats (n = 13 each). Representative neurograms of renal SNA recording at baseline and 6 hr after i.c.v.
leucine (5 mg, D), time course of renal SNA responses to i.c.v. vehicle (Veh) versus leucine (Leu) (5 mg, E), and averages of the last hour of renal SNA (F) after i.c.v.
vehicle, leucine (1 or 5 mg), or valine (5 mg) are shown.
(G and H) Arterial pressure response to i.c.v. leucine and valine in rats (n = 13 each). Time course of mean arterial pressure (MAP) response to i.c.v. vehicle versus
leucine (5 mg, G) and averages of the last hour of MAP (H) following i.c.v. vehicle, leucine (1 or 5 mg), or valine (5 mg) are shown.
(I) Effect of i.c.v. injection of 5 mg of leucine or valine on blood flow (conductance) recorded from various vascular beds in rats (averages of the last hour of
recordings are displayed, n = 13–15).
(J) Peak decrease in MAP in i.c.v. vehicle- and leucine (5 mg)-treated rats after a bolus i.v. injection of hexamethonium (1 mg/g body weight, n = 5–6).
Data are presented as the mean ± SEM. *p < 0.05 versus vehicle; yp < 0.01 versus vehicle and valine.
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cells, leucine stimulated S6K in a time-dependent manner (Fig-
ure 1A) as reported previously (Morrison et al., 2007; Cota
et al., 2006; Blouet et al., 2008).We also performed in vivo exper-
iments in rats to test the effect of leucine when administered in-
tracerebroventricularly (i.c.v.) into the third cerebral ventricle,
which is anatomically adjacent to the hypothalamus. As shown
previously (Cota et al., 2006; Blouet et al., 2009), i.c.v. leucine
(5 mg) activated hypothalamic mTORC1 signaling, as indicated
by the robust and time-dependent increase in phosphorylated
levels of S6K (p-S6K, Figure 1B) and S6 (p-S6, Figure 1C).
Notably, the increase in mTORC1 signaling was restricted to
the hypothalamus; no increase in p-S6K and p-S6 was detected
in extrahypothalamic regions such as the hippocampus, cortex,
or brainstem (Figures S1A and S1B available online, and data not
shown). Thus, third-ventricle i.c.v. leucine activates themTORC1
signaling pathway specifically in the hypothalamus.
We then assessed the sympathetic and hemodynamic effects
of hypothalamic mTORC1 activation with i.c.v. leucine. Sympa-
thetic nerve activity (SNA) was recorded directly from the nerve600 Cell Metabolism 17, 599–606, April 2, 2013 ª2013 Elsevier Inc.fibers subserving the kidney and measured simultaneously
with arterial pressure in anesthetized rats (Rahmouni and Mor-
gan, 2007). We found that i.c.v. administration of leucine (1 and
5 mg) caused a significant, dose-dependent increase in renal
SNA (Figures 1D–1F) and a parallel, dose-related rise in arterial
pressure (Figures 1G and 1H). The pressor effect of i.c.v. leucine
was reproduced using radiotelemetric measurement in freely
moving, conscious rats (Figures S1C–S1F). Notably, the in-
crease in arterial pressure was associated with a significant
decrease in the blood flow recorded from various arteries—
aortic, iliac, mesenteric, and renal—with variable intensity
(Figure 1I).
To investigate whether i.c.v.-leucine-induced arterial pressure
elevation was dependent on the sympathetic outflow, we as-
sessed the effect of ganglionic blockade with hexamethonium
(1 mg/g body weight, intravenously [i.v.]). The magnitude of the
arterial pressure decrease caused by hexamethonium was
significantly greater in leucine-treated rats than in controls (Fig-
ure 1J), highlighting the importance of sympathetic transmission
in mediating the pressor effect of i.c.v. leucine.
Figure 2. The Sympathetic and Hemodynamic Actions of Hypotha-
lamic Leucine Are Mediated by mTORC1 Signaling
(A and B) Effects ofmTORC1 inhibitionwith i.c.v. rapamycin (Rap; 10 ng) on the
i.c.v. leucine (5 mg)-induced increase in p-S6K (Thr389, A) and p-S6 (Ser240/244,
B) in rat mediobasal hypothalamic explants (n = 4 each).
(C–E) Effects of i.c.v. pretreatment with rapamycin (10 ng) on the renal SNA
(C), MAP (D), and renal blood flow (E) responses evoked by 5 mg of leucine i.c.v.
(n = 10–15).
Data are presented as the mean ± SEM. *p < 0.05 versus other groups.
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which does not activate mTORC1 signaling in the GT1-7 cell line
(Figure 1A) or in mediobasal hypothalamic explants (Figures
S1G), failed to alter renal SNA (Figure 1F), arterial pressure (Fig-
ure 1H), or regional blood flows (Figure 1I), indicating that the
sympathetic and hemodynamic responses to leucine are
specific.
It is interesting to note that a previous study reported elevated
circulating leucine in hypertensive subjects (Newgard et al.,
2009). Moreover, plasma leucine levels correlated with cardio-
vascular events and even predicted their occurrence (Shah
et al., 2010, 2012). These reports combined with our findings
suggest circulating leucine as a major cardiovascular risk factor.
We therefore investigated whether systemic administration of
leucine will alter SNA and arterial pressure in rats. Infusion of
leucine (1 mg/kg, i.v.) caused a slow but significant increase in
renal SNA, with a 76% ± 10% increase in the sixth hour (Fig-
ure S1H). This was associated with a 13 ± 4 mmHg elevation in
mean arterial pressure (Figure S1I). Notably, transection of the
renal nerve distal to the recording site did not affect the sympa-
thetic activation (84% ± 9% increase) caused by i.v. administra-
tion of leucine, demonstrating that leucine stimulated efferent
rather than afferent sympathetic traffic, which is consistent
with a centrally mediated effect of leucine.
Rapamycin Inhibits the Sympathetic and Cardiovascular
Effects of Leucine
To confirm that the hypothalamic effects of leucine are mediated
by mTORC1 signaling, we tested the renal SNA and arterial
pressure responses to leucine in the presence of rapamycin.
As expected, i.c.v. pretreatment with rapamycin (10 ng) blocked
the increase in hypothalamic p-S6K and p-S6 caused by i.c.v.
leucine (Figures 2A and 2B). In addition, i.c.v. pretreatment
with rapamycin abolished the leucine-induced increase in both
renal SNA (Figure 2C) and arterial pressure (Figure 2D), as well
as the reduction in renal blood flow (Figure 2E). Together, these
data demonstrate that hypothalamic mTORC1 plays an impor-
tant role in controlling SNA and cardiovascular function.
mTORC1 Mediates the Sympathetic and Cardiovascular
Actions of Leptin
The mTORC1 pathway has emerged as a critical signaling
mechanism of the leptin receptor in the hypothalamus (Cota
et al., 2006; Blouet et al., 2008). Given the compelling evidence
supporting the notion that brain action of leptin promotes sym-
pathoexcitation and arterial pressure increase (Hall et al., 2010;
Harlan et al., 2011a), we hypothesized that mTORC1 activation
is required for the sympathetic and hemodynamic responses
induced by leptin. In rats, i.c.v. administration of leptin (10 mg)
activated hypothalamic mTORC1 signaling (Figures 3A and
3B). Leptin (i.c.v.) caused no significant change in mTORC1
signaling in extrahypothalamic regions such as the hippocam-
pus, cortex, and brainstem (data not shown). Pretreatment
with rapamycin completely abolished leptin-evoked activation
of mTORC1 signaling (Figures 3A and 3B). Moreover, i.c.v. pre-
treatment with rapamycin substantially reduced the leptin-
induced increase in renal SNA (Figure 3C) and arterial pressure
(Figure 3D). We also tested the effects of rapamycin on the
sympathetic and hemodynamic effects induced by anotherCstimulus, melanotan II (MTII), which activates the melanocortin
3 and 4 receptors that have been implicated as downstream
mediators of the sympathetic and cardiovascular actions of
leptin (Hall et al., 2010; Rahmouni et al., 2003b). However, pre-
treatment with rapamycin had no effect on i.c.v. MTII-induced
increases in renal SNA or arterial pressure (Figures S2A and
S2B), indicating that blockade of sympathetic and cardiovascu-
lar effects of leptin by rapamycin is upstream of the melanocor-
tin system.
The evidence implicating the hypothalamic arcuate nucleus
(Arc) as the site of leptin’s action to increase sympathetic traffic
and arterial pressure (Harlan et al., 2011a; Rahmouni and Mor-
gan, 2007) prompted us to test whether blocking mTORC1
signaling in the Arc is sufficient to inhibit the sympathetic and
hemodynamic effects of leptin. To do this, an adenoviral vector
expressing a dominant-negative form of S6K (AdDNS6K) (Blouet
et al., 2008) was delivered specifically to the Arc via bilateral ste-
reotaxic microinjections. Adenovirus expressing GFP (AdGFP)
was used as a control and coinjectedwith the AdDNS6K for facil-
itating the identification of the infected region (Figure 3E). The
effectiveness of AdDNS6K in inhibiting S6K signaling was vali-
dated in the hypothalamic GT1-7 cell line and the Arc (Figures
S2C and S2D and previous studies by Blouet et al., 2008 and
Ono et al., 2008).
We then examined the effect of selectively decreasing
mTORC1 signaling in the Arc on the sympathetic response
evoked by i.v. administration of leptin (0.75 mg/g). Interestingly,
overexpression of DNS6K in the Arc decreased baseline renalell Metabolism 17, 599–606, April 2, 2013 ª2013 Elsevier Inc. 601
Figure 3. Critical Role of Hypothalamic
mTORC1 Signaling in the Sympathoexcita-
tory and Pressor Effects of Leptin
(A and B) Effects of pretreatment with i.c.v. rapa-
mycin (10 ng) on the i.c.v. leptin (10 mg)-induced
increase in hypothalamic p-S6K (Thr389, A) and
p-S6 (Ser240/244, B) in rats (n = 4–5).
(C and D) Renal SNA (C) and MAP (D) responses to
i.c.v. leptin (10 mg) in the absence or presence of
rapamycin (10 ng) administered i.c.v. in rats (n = 8
each).
(E) GFP staining (counterstained with DAPI) in the
Arc of a rat that received bilateral microinjection of
AdGFP into this nucleus. Scale bar represents
100 mm.
(F and G) Comparison of baseline renal SNA (F) and
MAP (G) between rats that received AdDNS6K
1 week earlier (with AdGFP) or AdGFP alone (con-
trol group) hitting the Arc (n = 5–11).
(H and I) Renal SNA response to i.v. infusion of
leptin (0.75 mg/g body weight) in rats that received
AdDNS6K or AdGFP hitting the Arc. (I) Renal SNA
response to leptin was compared between rats that
received AdDNS6K microinjections, which ‘‘hit’’ or
‘‘missed’’ the Arc (n = 5–11).
Data are presented as the mean ± SEM. *p < 0.05
versus other group(s).
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Hypothalamic mTORC1 and Cardiovascular RegulationSNA and arterial pressure (Figures 3F and 3G). Notably, these ef-
fects are absent in the leptin receptor mutant Zucker rats (Fig-
ures S2E and S2F). We also found that overexpression of
DNS6K in the Arc virtually eliminated the renal sympathoexcita-
tion caused by i.v. leptin (Figures 3H and 3I). Administration of
leptin i.v. caused a modest increase in arterial pressure (6 ±
6 mmHg), which was reversed (2 ± 6 mmHg) when Arc mTORC1
signaling was blocked with the DNS6K. Notably, the renal SNA
response to leptin in rats that underwent AdDNS6K microinjec-
tion wherein the injectionsmissed the Arc did not differ from con-
trol rats treated with AdGFP (Figure 3I). Moreover, bilateral
microinjection of AdDNS6K into the ventromedial hypothalamus,
which is adjacent to the Arc, failed to alter the renal SNA
response evoked by leptin (Figure S2G). Together, these results
implicate mTORC1 in the Arc as a key downstream pathway in
the control of renal SNA and arterial pressure by leptin.602 Cell Metabolism 17, 599–606, April 2, 2013 ª2013 Elsevier Inc.PI3K Links the Leptin Receptor to
mTORC1 Signaling
To gain insight into the mechanisms
mediating leptin-receptor activation of
mTORC1 signaling, we investigated the
role of the PI3K, which is a critical up-
stream element in the intracellular
cascade regulating mTORC1 signaling
(Hay and Sonenberg, 2004; Wang et al.,
2006). Leptin stimulates hypothalamic
PI3K through insulin receptor substrates
(IRS) (Niswender et al., 2001; Rahmouni
et al., 2009), and inhibition of PI3K
signaling blocks the renal SNA response
to leptin (Rahmouni et al., 2003a, 2009).
Therefore, we postulated that PI3Ksignaling links the leptin receptor to mTORC1 in the control
of renal SNA and arterial pressure. To test this, we first
evaluated the effect of pharmacological blockade of PI3K (using
LY29004 or wortmannin) on leptin-induced stimulation of
mTORC1 signaling. Leptin activation of S6 was blocked by
LY29004 and wortmannin in hypothalamic GT1-7 cells
that were transfected with ObRb, the long-signaling form of the
leptin receptor (Figures 4A and 4B). Knockdown of the catalytic
p110a subunit of PI3K (Figure S3A) also inhibited the leptin
activation of S6 in GT1-7 cells (Figure 4C). Moreover, pretreat-
ment with LY29004 abolished the ability of i.c.v. leptin to
increase hypothalamic p-S6K and p-S6 in mice (Figure 4D and
data not shown).
Second, we used two contrasting mouse models with either
an abolished or an enhanced effect of leptin on PI3K: the lep-
tin-resistant p110aD933A/WT mice, which carry a knockin
Figure 4. PI3K Mediates Leptin-Induced mTORC1 Activation, Sympathoexcitation, and Arterial Pressure Increase
(A–C)Western blot analysis of the effect of PI3K blockade (A, LY294002 [LY]; B, wortmannin [Wort]; and C, knockdown of p110a subunit with siRNA) on the leptin-
induced increase in p-S6 (Ser240/244) in hypothalamic GT1-7 cells transfected with the leptin receptor (ObRb, n = 4 each).
(D) Effect of PI3K inhibition (i.c.v. LY294002, 0.1 mg) on the i.c.v. leptin (2 mg)-induced increase in p-S6 (Ser240/244) in the mediobasal hypothalamus of C57BL/6J
mice (n = 4 each).
(E and F) Comparison of p-S6 (Ser240/244) levels in the Arc of wild-type (WT), PtenDObRb, and p110aD933A/WTmice that were treatedwith vehicle or leptin (60 mg, i.p.)
(n = 3 each).
(G–I) Renal SNA response (G, time course; H and I, average of last hour) to i.c.v. vehicle, leptin (2 mg), or MTII (100 pM) in WT, PtenDObRb, and p110aD933A/WT mice
(n = 3–17).
(J andK)Comparison of baseline radiotelemetricMAP (J, hourly averagesover 24 hr; K, 24 hr averages) betweenWT,PtenDObRb, andp110aD933A/WTmice (n =4–8).
(L) MAP response to leptin (60 mg, i.p.) in WT, PtenDObRb, and p110aD933A/WT mice (n = 4–8).
Data are presented as the mean ± SEM. *p < 0.05 versus vehicle controls; yp < 0.05 versus WT mice.
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2006), and the leptin-sensitive PtenDObRb mice, which have the
lipid phosphatase Pten (phosphatase and tensin homolog)
ablated in cells expressing the ObRb, leading to an enhanced
PI3K pathway specifically in leptin-sensitive neurons (Plum
et al., 2007). To avoid differences in body weight as a variable,
we used mutant mice with body weights matching those of
the littermate controls (Figures S3B and S3C). Notably, the
PtenDObRb mice had elevated p-S6 staining in the Arc, at base-
line and in response to leptin, as detected by immunohisto-
chemistry (Figure 4E and 4F). Conversely, the p110aD933A/WT
mice had reduced p-S6 immunoreactivity in the Arc, both at
baseline and in response to leptin (Figures 4E and 4F). In line
with a recent report (Dagon et al., 2012), these data implicate
PI3K as a mediator underlying leptin receptor activation of
mTORC1 signaling. It should be noted, however, that both
Pten and p110a are major regulators of mTORC1 activity.
Thus, the altered baseline mTORC1 activity in the Arc of
PtenDObRb mice and p110aD933A/WT mice may be expected.
Additional experiments are needed to determine the contribu-
tion of leptin to the changes in baseline mTORC1 activity in
the Arc of the two mouse models.
PI3K Activity Is Crucial for the Sympathetic and
Cardiovascular Effects of Leptin
Lastly, we assessed the sympathetic and cardiovascular ramifi-
cations of the contrasting change in the activity of the PI3K-
mTORC1 axis. Relative to control mice, the PtenDObRb mice
had a strikingly enhanced renal SNA response to i.c.v. leptin,
whereas the p110aD933A/WT mice displayed a blunted response
(Figures 4G and 4H). In contrast, the MTII-induced renal SNA in-
crease was similar in PtenDObRb, p110aD933A/WT, and control
mice (Figure 4I), arguing for the specificity of the altered renal
SNA responses to leptin. The lack of arterial pressure response
to i.c.v. leptin in anesthetized mice (Harlan et al., 2011b)
prompted us to use radiotelemetry to assess the hemodynamic
consequences of the bidirectional change in PI3K-mTORC1
activity. Interestingly, baseline arterial pressure was elevated
in PtenDObRb mice compared to controls, whereas the
p110aD933A/WT mice had a normal baseline arterial pressure
(Figures 4J and 4K). However, alteration of PI3K signaling in
mice did not alter heart rate (Figures S3D and S3E). Finally, we
examined the effect of leptin on arterial pressure in the two
mouse models. The leptin-induced arterial pressure increase
was enhanced in PtenDObRb mice but blunted in p110aD933A/WT
mice (Figure 4L). In PtenDObRb mice, leptin also attenuated
the arterial pressure decrease caused by fasting (Fig-
ure S3F). Together, these findings demonstrate the importance
of the PI3K pathway for sympathetic and hemodynamic regula-
tion by leptin.
This study identifies a role for hypothalamic mTORC1 in the
regulation of sympathetic nerve traffic and arterial pressure.
Our data also indicate the importance of PI3K-mTORC1
signaling in mediating the sympathetic and hemodynamic
effects of leptin. Our findings broaden the role of hypothalamic
mTORC1 signaling, which has previously been implicated in
the control of other physiological processes such as feeding
(Blouet et al., 2008; Cota et al., 2006), glucose metabolism
(Ono et al., 2008), and reproductive function (Roa et al., 2009).604 Cell Metabolism 17, 599–606, April 2, 2013 ª2013 Elsevier Inc.The ability of mTORC1 to sense and integrate various signals,
combined with its prominent role in the control of a plethora of
cellular processes ranging from gene transcription to neuronal
excitability, raises the possibility that mTORC1 may serve as a
‘‘molecular hub’’ that allows hypothalamic neurons to integrate
various inputs including hormones and nutrients for the produc-
tion of coordinated responses that maintain homeostasis, with
potential pathophysiological consequences. Indeed, hyperac-
tive hypothalamic mTORC1 signaling has recently been impli-
cated in age-related obesity (Yang et al., 2012). Moreover,
inhibition of mTORC1 signaling (via rapamycin treatment or dele-
tion of the s6k1 gene) extends lifespan in mice (Harrison et al.,
2009; Selman et al., 2009). It will be interesting to examine
whether hypothalamic mTORC1 activation accounts for the
sympathetic overdrive, hypertension, and deteriorating cardio-
vascular health that are commonly associated with aging (Seals
and Dinenno, 2004; North and Sinclair, 2012).
EXPERIMENTAL PROCEDURES
Animals
All animal protocols were approved by the University of Iowa Animal Research
Committee. Details about the strains of rats and mice used are provided in the
Supplemental Information.
Hypothalamic mTORC1 Signaling
Animals were fasted for 3 hr before i.c.v. injections. Animals were killed at the
indicated time points via CO2 asphyxiation. The mediobasal hypothalamus
was quickly removed from each animal. The total proteins were extracted
using lysis buffer and processed for western blotting.
Sympathetic Nerve Recording
Renal SNA was assessed using multifiber recording. In brief, anesthesia was
induced with intraperitoneal (i.p.) injection of a ketamine (91 mg/kg) and xyla-
zine (9.1 mg/kg) cocktail and sustained with i.v. administration of a-chloralose
(6 mg/kg/hr). The renal nerve was identified and mounted on bipolar platinum-
iridium electrodes, and the ensemble was fixed with silicone gel. Background
noise was excluded in the assessment of renal SNA by correcting for postmor-
tem activity.
Regional Blood Flows
Rats were anesthetized i.p. with the ketamine/xylazine cocktail. After careful
dissection and separation of each artery, individual Doppler ultrasound probes
were placed around the left renal artery (0.8 mm in diameter), superior mesen-
teric artery (1.0 mm), left iliac artery (1.0 mm), and lower abdominal aorta
(1.3 mm). Once a clear Doppler echo signal was achieved, each probe was
securely tied into place, and wires were tunneled subcutaneously out of the
nape of the animal’s neck.
Data Analysis
Data are expressed as means ± SEM and analyzed using one- or two-way
ANOVA with or without repeated measure. When analysis of ANOVA reached
significance, appropriate post hoc tests were used. A value of p < 0.05 was
considered statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.cmet.2013.02.017.
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